Table 1 Correlation of miR-663 methylation with clinical features in pediatric AML patients
From: The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML)
Patient’s parameter | Status of miR-663 methylation | |||
|---|---|---|---|---|
Methylated (n = 29) | Unmethylated (n = 41) | Total | P value | |
Age(median and range, year) | 6.12(1–13) | 6.72(1–11) | 6.47(1–13) | 0.879 |
Gender (male and female) | 16/13 | 18/23 | 34/36 | 0.602 |
Laboratory parameters (median and range ) | ||||
WBC (10 9 /L) | 15.3(0.8-51.1) | 17.2(0.8-43.6) | 16.4(0.8-51.1) | 0.800 |
Hemoglobin (g/L) | 77.3(32–176) | 70.3(32–107) | 73.2(32–176) | 0.203 |
Platelet count (10 9 /L) | 54.2(12–310) | 73.6(23–273) | 65.54(12–310) | 0.194 |
FAB subtype, n | ||||
M1 | 0 | 12 | 12 | |
M2 | 18 | 14 | 32 | |
M3 | 0 | 10 | 10 | |
M4 | 5 | 0 | 5 | |
M5 | 6 | 5 | 11 | 0.264 |
miR-663 transcript | 2.84 | 2.64 | 2.67 | 0.827 |